Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company committed to enhancing drug delivery and efficacy through its proprietary PRINT® technology. The company focuses on the development, manufacturing, and commercialization of innovative therapies for pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s flagship product, YUTREPIA™, is an investigational inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and PH-ILD. This product aims to improve exercise ability and quality of life for patients.
Liquidia is actively advancing its product pipeline, which includes L606, an investigational sustained-release formulation of treprostinil administered through a next-generation nebulizer. Currently, L606 is under evaluation in an open-label study and aims to extend drug exposure while minimizing local irritation in the lungs.
In addition to these developments, Liquidia has a valuable collaboration with leading pharmaceutical companies, leveraging its PRINT® technology for broader therapeutic areas. This technology enables precise production of uniform drug particles, enhancing safety and efficacy, and can be applied to various therapeutic areas and routes of administration.
Recent achievements include the promotion of key leadership within the company as they prepare for the potential FDA approval and launch of YUTREPIA. The company has also successfully navigated regulatory and legal challenges, ensuring a clear path for YUTREPIA’s market entry.
Financially, Liquidia has demonstrated robust growth, reporting significant revenue from its partnership with Sandoz for the commercial sale of Treprostinil Injection. The company has also secured substantial funding through strategic agreements, bolstering its cash reserves for continued research and development efforts.
Liquidia remains dedicated to transforming patient care by addressing unmet needs with innovative drug delivery solutions and is poised to make significant strides in the biopharmaceutical industry.
Liquidia Corporation (NASDAQ: LQDA) will participate in two upcoming investor conferences: the BTIG Biotechnology Conference 2022 on August 8 in New York, featuring CFO Michael Kaseta's live Fireside Chat at 2:00 p.m., and the Wedbush PacGrow 2022 Healthcare Conference on August 9, a virtual event. The biopharmaceutical firm specializes in pulmonary hypertension treatments, including its product YUTREPIA™ (treprostinil) inhalation powder. More details can be found at www.liquidia.com.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of a stock option for 2,000 shares to a new non-executive employee under its 2022 Inducement Plan. This option is part of the employee's compensation, aligning with Nasdaq Listing Rule 5635(c)(4). The stock option, exercisable at $5.20 per share, has a ten-year term and vests over four years, with 25% vesting after the first year and monthly vesting thereafter. Liquidia focuses on developing products for pulmonary hypertension utilizing its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced the approval of an employment inducement equity award for Dr. Rajeev Saggar, its new Chief Medical Officer. The award consists of a stock option for 200,000 shares under the Liquidia Corporation 2022 Inducement Plan, granted as a material inducement for his employment. The stock option is exercisable at $3.73 per share, with a ten-year term and a four-year vesting schedule. This strategic move aligns with Liquidia's focus on developing treatments for pulmonary hypertension and related conditions.
Liquidia Corporation (NASDAQ: LQDA) received a favorable ruling from the U.S. Patent Trial and Appeal Board regarding the unpatentability of all claims in U.S. Patent No. 10,716,793, owned by United Therapeutics Corporation. This decision supports the potential final regulatory approval of YUTREPIA, an investigational inhaled drug for pulmonary arterial hypertension (PAH). However, ongoing litigation regarding additional patents may delay YUTREPIA's approval until 2027 or later. The PTAB ruling does not guarantee resolution of the litigation.
Liquidia Corporation (LQDA) announced its inclusion in the US small-cap Russell 2000® Index effective June 27, 2022, signaling growth and increased visibility among institutional investors. This membership, valid for one year, follows Liquidia’s performance within the broader Russell 3000® Index. CEO Roger Jeffs stated this reflects the positive momentum generated over recent years, especially as the company prepares for the potential launch of YUTREPIA®, its inhalation powder product pending FDA approval.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options for a total of 24,800 shares to newly hired non-executive employees under its 2022 Inducement Plan. Each stock option, exercisable at $5.79 per share, represents a component of the employment compensation for the new hires. The options have a ten-year term and vest over four years. This plan complies with Nasdaq Listing Rule 5635(c)(4) and is intended to attract and retain talent within the company.
Liquidia Corporation (NASDAQ: LQDA) granted a stock option for 2,000 shares of its common stock to a newly hired non-executive employee, as part of the 2022 Inducement Plan. This option, exercisable at $4.58 per share, aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducements for new hires. The stock option vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. Liquidia focuses on developing treatments for pulmonary hypertension using its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced the appointment of Dr. Rajeev Saggar as Chief Medical Officer, effective July 18, 2022. Dr. Saggar, an expert in pulmonary diseases, will lead the company's research and regulatory affairs, assisting in the anticipated launch of YUTREPIA™, an inhalation powder for pulmonary arterial hypertension, pending final FDA approval. CEO Roger Jeffs highlighted Dr. Saggar’s extensive experience in clinical development and patient care as vital for Liquidia's growth trajectory. This leadership change is expected to enhance the development of innovative therapies.
Liquidia Corporation (NASDAQ: LQDA) recently presented data on the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the Pulmonary Hypertension Association (PHA) International Conference in Atlanta from June 9-11, 2022. The research focused on Quality of Life (QoL) improvements for pulmonary arterial hypertension (PAH) patients, emphasizing the positive impact of YUTREPIA in both new treatments and transitions from other therapies. The FDA previously issued a tentative approval for YUTREPIA on November 5, 2021, which aims to enhance exercise ability for patients with NYHA Functional Class II-III symptoms.
Liquidia Corporation (NASDAQ: LQDA) has announced its participation in the Jefferies Healthcare Conference, where CFO Michael Kaseta will engage in a fireside chat on June 9, 2022, at 8:00 am ET. The conference runs from June 8 to 10, 2022, in New York City. Investors can access a live webcast of the event on Liquidia’s website, which will be archived for 30 days after the conference.
Liquidia focuses on developing products for pulmonary hypertension using its PRINT® Technology, including its inhalation powder YUTREPIA™ for treating pulmonary arterial hypertension.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's primary focus?
What is YUTREPIA?
What is PRINT® technology?
What products are in Liquidia’s pipeline?
How does Liquidia generate revenue?
What recent leadership changes have occurred at Liquidia?
What is the current status of YUTREPIA’s FDA approval?
What are the financial highlights for Liquidia?
What legal challenges has Liquidia faced?
How can I learn more about Liquidia Corporation?
